Immunotherapy plus an investigational cancer drug improves anti-tumor effects
An investigational therapy for solid tumors could be especially effective when combined with immunotherapy to target a specific kind of cancer cell, a research team at Duke and Harvard have found.
Led by Lee Zou, Ph.D., chair of Duke’s Department of Pharmacology & Cancer Biology, the researchers focused on the way some cancer cells impede normal DNA repair to fuel tumor formation. This phenomenon is known as defective DNA mismatch repair.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
More News: Biology | Cancer | Cancer & Oncology | Drugs & Pharmacology | Gastroschisis Repair | Harvard | Immunotherapy | Pharmaceuticals